You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Educational program offers unique resources to empower transplant patients and their caregivers DEERFIELD, IL, October 17, 2007 – Astellas Pharma US, Inc., a leader in the field of...
Reaffirms 2007 Global Tarceva Sales Guidance MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 15, 2007--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided commentary today on third quarter U.S. Tarceva sales....
Read more about OSI Pharmaceuticals Provides Additional Information about US Sales of Tarceva
DEERFIELD, IL, October 11, 2007 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the third annual Astellas Ride of a Lifetime contest. Launched...
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that the Company has received Notice of Final Determination from the US Patent and...
Read more about OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
MELVILLE, N.Y., Sep 07, 2007 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of selected data from over 58 studies involving the Company's lead product,...
Follow U.S. news
